Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported Q4 2025 results, with $3.9 billion in revenue (+3.0% YoY) and adjusted EPS of $11.44, beating street expectations. President and CEO highlighted success in 2025, with growth driven by blockbuster medicines like EYLEA HD, Dupixent, and Libtayo.

BofA Securities maintained Buy rating and $860 price target on REGN, citing strong performance and future growth potential. Expected Q4 collaboration revenues and estimated 2026 revenues were factors in the reaffirmed rating, highlighting prospects for EYLEA HD, Dupixent, and the company’s pipeline opportunities.

Evercore ISI raised price target on REGN to $875 and reiterated Outperform rating, emphasizing Dupixent’s growth momentum and the upcoming EYLEA HD launch. Regeneron Pharmaceuticals, Inc. is a top biotechnology company based in New York, focusing on eye, cardiovascular, cancer, and inflammatory treatments for severe illnesses.

Read more at Yahoo Finance: Regeneron Pharmaceuticals, Inc. (REGN) Posts Q4 Earnings Beat, EPS Shines